{"schema_version":"secwatch.filing_event.v1","accession":"0001555280-23-000072","form_type":"8-K","ticker":"ZTS","cik":"0001555280","company_name":"Zoetis Inc.","filed_at":"2023-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.555164+00:00","generated_at":"2026-06-19T13:45:56.884072+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Zoetis Q4 revenue $2.0B (+9% operational); adj. EPS $1.15; FY23 guide $8.575-8.725B","bullets":["Q4 revenue $2.0B (+4% reported, +9% operational); net income $461M ($0.99 EPS); adj. net income $539M ($1.15 adj. EPS).","Full year 2022 revenue $8.1B (+4% reported, +8% operational); adj. net income $2.3B ($4.88 adj. EPS).","U.S. segment revenue $1.112B (+7%), driven by Simparica Trio and dermatology brands Apoquel and Cytopoint.","International segment revenue $901M (flat reported, +12% operational), led by parasiticides and dermatology.","FY23 guidance: revenue $8.575-8.725B (6-8% operational growth); adj. diluted EPS $5.34-5.44."],"urls":{"canonical":"https://secwatch.observer/filing/0001555280-23-000072","json":"https://secwatch.observer/filing/0001555280-23-000072.json","markdown":"https://secwatch.observer/filing/0001555280-23-000072.md","text":"https://secwatch.observer/filing/0001555280-23-000072.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1555280/000155528023000072/0001555280-23-000072-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1555280/000155528023000072/zts-20230214.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T13:45:56.884072+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"557af42ac0ce93fdb81ab31a7bc862215a83b3b1","claim":"Zoetis Inc. reported Full Year 2023 results: revenue $8.575 - $8.725 Billion, EPS $5.03 to $5.14 on a Reported Basis, or $5.34 to $5.44 on an Adjusted Basis. Guidance initiated.","evidence_excerpt":"Provides Full Year 2023 Revenue Guidance of $8.575 - $8.725 Billion, with Diluted EPS of $5.03 to $5.14 on a Reported Basis, or $5.34 to $5.44 on an Adjusted Basis","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1555280/000155528023000072/0001555280-23-000072-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Full Year 2023"},{"label":"Revenue","value":"$8.575 - $8.725 Billion"},{"label":"EPS","value":"$5.03 to $5.14 on a Reported Basis, or $5.34 to $5.44 on an Adjusted Basis"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"773b324b400533fef3222460ee007199df4a2ffc","claim":"Zoetis Inc. reported Full Year 2022 results: revenue $8.1 Billion, net income $2.1 Billion, or $4.49 per Diluted Share.","evidence_excerpt":"For Full Year 2022, Zoetis Reports Revenue of $8.1 Billion, Growing 4%, and Net Income of $2.1 Billion, or $4.49 per Diluted Share, on a Reported Basis","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1555280/000155528023000072/0001555280-23-000072-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Full Year 2022"},{"label":"Revenue","value":"$8.1 Billion"},{"label":"Net income","value":"$2.1 Billion, or $4.49 per Diluted Share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"8517815f19e51ff46a7583b8cfd1cd394f47fd74","claim":"Zoetis Inc. reported the fourth quarter and full year 2022 results: revenue $2.0 Billion, net income $461 Million, or $0.99 per Diluted Share. Guidance initiated.","evidence_excerpt":"specific reference in such a filing. --- EX-99.1 (EX-99.1) --- Zoetis Reports Fourth Quarter and Full Year 2022 Results • For Fourth Quarter 2022, Zoetis Reports Revenue of $2.0 Billion, Growing 4%, and Net Income of $461 Million, or $0.99 per Diluted Share, on a Reported Basis ◦ Delivers 9% Operational Growth in Revenue and 27% Operational Growth in Adjusted","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1555280/000155528023000072/0001555280-23-000072-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year 2022"},{"label":"Revenue","value":"$2.0 Billion"},{"label":"Net income","value":"$461 Million, or $0.99 per Diluted Share"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}